Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma
Discover our news
Boston Business Journal Names Servier Pharmaceuticals a Best Places to Work for the Fourth Consecutive Year
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore
